Biotechnology News

LOS ANGELES, CA, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced...

STERLING, Va., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Capra Biosciences, Inc., a biomanufacturing company leveraging modular, continuous bioreactor technology to enable flexible, cost-competitive...

Discussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating...

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to...

Second quarter revenue of $30M, +43% year-over-year growth; IFRS gross margin of 76.5%Second quarter usage fee revenue of $13.9M, 52.2% year-over-year growthFirst half revenue of $54.4M, +44%...

TEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that post-hoc data from its...

Dose-finding Phase 1b study (n=240) on track for topline data in September 2026CANYON-1 follows promising data from Phase 1a SAD/MAD study that demonstrated differentiated GI tolerability from GLP-1...

ATLANTA and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine...

RADNOR, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related...

Data support ongoing Phase 2 “RENEW” trialFirst-in-human clinical study produced measurable reductions in multiple markers of lung scarring and inflammation in IPF patientsStudy confirms LTI-03 was...